What Are Analysts Saying About Pfizer?

After a lackluster start to 2016, Pfizer’s (PFE) stock price is currently trending upwards, albeit at a slow pace. The performance of Pfizer according to a historical stock chart indicates a clear downward trend from May 2015 all the way through to February 2016. However, a reversal appears to be taking place with bullish momentum driving the price towards the $30 per share level, and strong consolidation around that priceline for the past 2 months. The most recent dividend and split history for the stock reflects the following:

03-02-2016 a dividend amount of $0.30 in regular cash was paid out

12-01-2015 a dividend of $0.28 in regular cash was paid out

09-02-2015 a dividend of $0.28 in regular cash was paid out

06-02-2015 a dividend of $0.28 in regular cash was paid out

pfizer

Pfizer stock is currently trading at $30.04, up 1.35%. The company has a 52-week low price of $28.25 and a 52-week high price of $36.46. The company’s market capitalization is $186,004.04 million. Pfizer trades on the New York Stock Exchange under the ticker PFE. On 31 March 2016, Pfizer released a statement assuaging investor concerns about a false press release directing readers to a false website. The fake website made multiple references to Pfizer, and the information therein was erroneous and misleading. The news however had little impact on the performance of the company’s stock at the time.

Strengths and Weaknesses

Analysts across the board have taken a long, hard look at Pfizer and its strengths and weaknesses. The consensus estimate among many analysts is that Pfizer is currently a strong buy, with a large minority of investors considering it a hold. Very few investors have any sell motivation for the stock. On a rating scale of buy – sell, analysts rate it as a hold. The company has multiple strengths and weaknesses, hence the mixed ratings assessment. The needle is unlikely to move in either direction – buy or sell – based on multiple factors. The strengths of the company are evident in things like revenue growth, a really stable financial position, and manageable debt levels. Pfizer also has the added advantage of expanding profit margins. But there also weaknesses in the mix and these include declining net income, a weak operating cash flow, and a poor return on equity. On a ratings scale of 1 to 5, with 1 being a strong buy and 5 being a strong sell, Pfizer is regarded as a 2.7. This pharmaceutical juggernaut is involved in the manufacture, research and development of various healthcare products around the world.